Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S5. MALDI-TOF MS analyses of MK-1775 (m/z 501.2)in brain and flank GBM22 tumor samples after treatment with placebo or MK-1775
Authors: Jenny L. Pokorny, David Calligaris, Shiv K. Gupta, Dennis O. Iyekegbe, Dustin Mueller, Katrina K. Bakken, Brett L. Carlson, Mark A. Schroeder, Debra L. Evans, Zhenkun Lou, Paul A. Decker, Jeanette E. Eckel-Passow, Vincenzo Pucci, Bennett Ma, Stuart D. Shumway, William F. Elmquist, Nathalie Y.R. Agar, Jann N. Sarkaria
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361909375